Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Immunome, Inc. (IMNM) reported a Q3 loss of $0.78 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is a larger loss compared to $0.36 per share a year ago.
November 13, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Immunome, Inc. reported a larger than expected Q3 loss of $0.78 per share, missing the consensus estimate of $0.60 and increasing from last year's $0.36 loss.
The larger than expected loss and the increase in loss compared to the previous year are likely to negatively impact investor sentiment, leading to a potential short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100